Andere Sprachen ViroGates A/S

Aktien

A2JP7J

DK0061030574

VIRO

Markt geschlossen - Nasdaq Copenhagen Andere Börsenplätze 16:59:52 26.04.2024			% 5 Tage	% 1. Jan.
6,5 ^DKK	-11,92 %		+8,33 %	+7,97 %

15.04.	Virogates A/S gibt das Ergebnis des Q-Submission-Antrags für Sobi®? Turbi Latex bei der US Food and Drug Administration	CI
21.03.	ViroGates A/S meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Resolutions from the Annual General Meeting of ViroGates A/S	25.04.
ViroGates announces the outcome of its Q-Submission filing for suPARnostic® TurbiLatex with the US FDA and the overall timeline for filing a submission of a 510k/“De Novo” application with the FDA	15.04.
Virogates A/S Announces the Outcome of Its Q-Submission Filing for Sobi®? Turbi Latex with the Us Food and Drug Administration	15.04.
ViroGates gives notice to convene the Annual General Meeting on 25 April 2024	10.04.
ViroGates announces its Annual Report 2023: Revenue was affected by the loss of COVID-19 customers and a difficult transition into general triage	21.03.
ViroGates A/S Reports Earnings Results for the Full Year Ended December 31, 2023	21.03.
Subscription of shares by majority shareholder in relation to the recently completed rights emission in ViroGates A/S	21.12.
ViroGates notification of transactions by persons discharging managerial responsibilities according to MAR art. 19	21.12.
ViroGates publishes its financial calendar for 2024	21.12.
ViroGates announces financial guidance for 2024	21.12.
ViroGates A/S Provides Earnings Guidance for the Year 2024	21.12.
ViroGates' capital raise of DKK 13.9 million and issue of 3,097,047 new shares have been registered	19.12.
ViroGates announces the outcome of its rights issue	15.12.
ViroGates A/S : Most interesting suPAR studies of 2023	08.12.
ViroGates notification of transactions by persons discharging managerial responsibilities according to MAR art. 19	07.12.
ViroGates A/S : Clinical role of suPAR in the prognosis of patients in the emergency setting and its influence on risk stratification	06.12.
The subscription period in ViroGates’ rights issue begins today	30.11.
Resolutions from the Extraordinary General Meeting of ViroGates A/S	24.11.
ViroGates A/S : Social isolation in mid-adulthood is associated with elevated suPAR	23.11.
ViroGates gives notice to convene an Extraordinary General Meeting on 24 November 2023	09.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen ViroGates A/S

Aktien

A2JP7J

DK0061030574

VIRO

Andere Sprachen

Filter